Alterity announces funding from Michael J. Fox Foundation for ATH434 dose optimization for Parkinson’s disease clinical trials February 9, 2021August 16, 2022
Initial data for Alterity Therapeutics Phase 1 clinical trial released at American Academy of Neurology Annual Meeting May 6, 2019August 16, 2022
Alterity Therapeutics presents data on ATH434 to the American Academy of Neurology May 21, 2020August 16, 2022